APA (7th ed.) Citation

Chung, C. H., Aulino, J., Muldowney, N. J., Hatakeyama, H., Baumann, J., Burkey, B., . . . Murphy, B. A. (2010). Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of Oncology, 21(4), 864. https://doi.org/10.1093/annonc/mdp390

Chicago Style (17th ed.) Citation

Chung, C. H., et al. "Nuclear Factor-kappa B Pathway and Response in a Phase II Trial of Bortezomib and Docetaxel in Patients with Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma." Annals of Oncology 21, no. 4 (2010): 864. https://doi.org/10.1093/annonc/mdp390.

MLA (9th ed.) Citation

Chung, C. H., et al. "Nuclear Factor-kappa B Pathway and Response in a Phase II Trial of Bortezomib and Docetaxel in Patients with Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma." Annals of Oncology, vol. 21, no. 4, 2010, p. 864, https://doi.org/10.1093/annonc/mdp390.